<DOC>
	<DOCNO>NCT00157274</DOCNO>
	<brief_summary>The investigator design compassionate basis phase II study refractory/relapsed mycosis fungoides/Sezary syndrome consist alemtuzumab ( Campath ) primary evaluation overall response time relapse . Other goal consider toxicity time new therapy .</brief_summary>
	<brief_title>Study Alemtuzumab Treat Advanced Mycosis Fungoides/Sezary Syndrome</brief_title>
	<detailed_description>- 20 relapsed refractory advance mycosis fungoides/Sezary syndrome patient schedule gradually escalate dos ( 3 mg , 10 mg , 30 mg ) sequential day first week , follow 30 mg three time week 12 week . - Patients must serology negative human T-lymphotropic virus 1 ( HTLV-1 ) three different regimen chemotherapy . - Follow one year last cycle alemtuzumab .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Mycosis Fungoides</mesh_term>
	<mesh_term>Sezary Syndrome</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<criteria>Above 18 year old Eastern Cooperative Oncology Group ( ECOG ) 02 Liver renal function test less twice upper label No active infection Written inform consent One three regimens previous chemotherapy Abnormal renal hepatic function Mycosis fungoides/Sezary syndrome transformation HIV + HTLV1 + Pregnancy Lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>Alemtuzumab</keyword>
	<keyword>Mycosis fungoides</keyword>
	<keyword>Sezary</keyword>
</DOC>